Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society
6 June 2025
GLP-1 medication use for type 2 diabetes has soared
however, since then, four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage
Other Ingredients: Gelatin, microcrystalline cellulose, silica, magnesium stearate
For individuals managing weight or blood glucose stability, this profile is significantly different from sucralose, aspartame, or stevia, which do not reliably stimulate GLP-1 secretion